构建值得信赖且具防御性的AI指南以满足利益相关者需求

IQVIA Healthcare-grade AI®ensures generative AI is harnessed responsiblyand with the speed, precision, and trust required for the healthcare industry. The information below explores how trustworthy, defensible AI provides industry confidence in the quality andaccuracy of generative AI in healthcare. We also present a case study that illustrates how AI capabilities and acomprehensive end-to-end workflow support emerging market needs. •Enabling data for good with an actionable frameworkto evaluate the uses of AI and when different tiers ofgovernance are needed to build a trusted system. Determining the path forward Life sciences and healthcare organizations havespecific needs that raise important questions aboutthe use of generative AI in guiding decision making.Emerging regulatory oversight and expectations inhow AI systems will be managed heightens the riskprofile of novel uses and applications for generativeAI. Unclear governance through principles-basedguidance for generative AI adds uncertainty regardingexpectations and risks. A lack of clarity around thisguidance can make it challenging for stakeholdersabout a clear path forward, ultimately slowingdecision making. •Adhering to regulations and user expectationsacross jurisdictions with formal assessment againstinternational standards in the management of AI. •Developing a pragmatic implementation frameworkthat provides a roadmap for greater transparencywith clear and actionable methods to improve safeAI efficiency. Life sciences and healthcareorganizations have specific needsthat raise important questions aboutthe use of generative AI in guidingdecision making. Moving forward throughcollaboration IQVIA collaborates with healthcare, technology andregulatory organizations globally to responsiblyaccelerate the evolution and adoption of AI inhealthcare and improve patient outcomes. We haveinformed 25+ guidelines represented in regulatoryguidance and standards worldwide (e.g., ISO, UK ICO). Gaining momentum throughalignment Implementing clear guidelines to satisfy regulatorexpectations and internal needs for driving businessoutcomes answers stakeholder questions about thesafe use and efficacy of generative AI in healthcare.Improved stakeholder alignment across variousfunctional teams regarding expectations and the pathforward help accelerate decision making. IQVIA Healthcare-grade AI®implements the followingguidelines to reduce confusion around expectationsand risks of using generative AI for decision makingand ensure stakeholder needs are met: IQVIA is recognized as the leader in generative AI expertise for RWEand Medical Affairs solutions Source: As determined by independent research on RWE/Medical Affairs Market landscape Solutions and servicesinformed by expertise in technology, data protection,and privacy to provide world-class guidance and solutions on safe uses ofpredictive and generative AI, part of IQVIA Applied AI Science Strategic planning for future AI,identifying emerging technologiesand developing strategic patientdata frameworks for safe data & AI Governance and managementof data and AI, aligning withregulatory expectations,operational goals, and newcapabilities like data mesh Data protection and privacytechniques,maintaining theintegrity and confidentiality ofdata and AI operations Case study: IQVIA Healthcare-grade AI®optimizes clientresearch monitoring for COVID-19 Delivering a living review literature database for a Top 10 pharma client Solution Situation The capabilities of IQVIA Healthcare-grade AI®enabled a “living review” database in which keypublications were continuously searched andselected for review and real world data extractedfrom the literature, giving the client increasedinsight into the desired research. To expeditethe literature review process, generative AI andNatural Language Processing (NLP) methods werecombined with IQVIA Evidence Synthesis expertiseto automate data curation, extraction and synthesis.Our Human Assisted Review Tool (HART) interfaceensured prompt validation of results with expertoversight to ensure accuracy. The volume and velocity of published researchrelated to COVID-19 is unprecedented in itsscale and diversity. The ongoing extraction ofinsights from such a rich and expansive amountof information posed a significant challenge for aTop 10 Pharma client seeking enhanced publicationmonitoring with efficient selection and accurateextraction from the most relevant and high-qualitypeer-reviewed articles. The ongoing extraction of insightsfrom such a rich and expansiveamount of information posed asignificant challenge. Continued on the next page...